These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration. Monine M; Norris D; Wang Y; Nestorov I J Pharmacokinet Pharmacodyn; 2021 Oct; 48(5):639-654. PubMed ID: 33991294 [TBL] [Abstract][Full Text] [Related]
8. [Antisense therapies for neurological diseases]. Pulst SM Nervenarzt; 2019 Aug; 90(8):781-786. PubMed ID: 31165208 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic antisense oligonucleotides for movement disorders. Doxakis E Med Res Rev; 2021 Sep; 41(5):2656-2688. PubMed ID: 32656818 [TBL] [Abstract][Full Text] [Related]
10. Antisense therapies for movement disorders. Scoles DR; Pulst SM Mov Disord; 2019 Aug; 34(8):1112-1119. PubMed ID: 31283857 [TBL] [Abstract][Full Text] [Related]
11. Antisense oligonucleotides: treating neurodegeneration at the level of RNA. DeVos SL; Miller TM Neurotherapeutics; 2013 Jul; 10(3):486-97. PubMed ID: 23686823 [TBL] [Abstract][Full Text] [Related]
12. Transcript-Targeted Therapy Based on RNA Interference and Antisense Oligonucleotides: Current Applications and Novel Molecular Targets. Barresi V; Musmeci C; Rinaldi A; Condorelli DF Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012138 [TBL] [Abstract][Full Text] [Related]
13. Making sense of antisense oligonucleotides: A narrative review. Goyal N; Narayanaswami P Muscle Nerve; 2018 Mar; 57(3):356-370. PubMed ID: 29105153 [TBL] [Abstract][Full Text] [Related]
14. Roles of long noncoding RNAs in brain development, functional diversification and neurodegenerative diseases. Wu P; Zuo X; Deng H; Liu X; Liu L; Ji A Brain Res Bull; 2013 Aug; 97():69-80. PubMed ID: 23756188 [TBL] [Abstract][Full Text] [Related]
15. Antisense therapy: a potential breakthrough in the treatment of neurodegenerative diseases. Romano R; Bucci C Neural Regen Res; 2024 May; 19(5):1027-1035. PubMed ID: 37862205 [TBL] [Abstract][Full Text] [Related]
16. Antisense oligonucleotides in therapy for neurodegenerative disorders. Evers MM; Toonen LJ; van Roon-Mom WM Adv Drug Deliv Rev; 2015 Jun; 87():90-103. PubMed ID: 25797014 [TBL] [Abstract][Full Text] [Related]
17. Antisense oligonucleotide therapies for Amyotrophic Lateral Sclerosis: Existing and emerging targets. Klim JR; Vance C; Scotter EL Int J Biochem Cell Biol; 2019 May; 110():149-153. PubMed ID: 30904737 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic Antisense Oligonucleotides Are Coming of Age. Bennett CF Annu Rev Med; 2019 Jan; 70():307-321. PubMed ID: 30691367 [TBL] [Abstract][Full Text] [Related]
19. Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders. Jablonka S; Hennlein L; Sendtner M Neurol Res Pract; 2022 Jan; 4(1):2. PubMed ID: 34983696 [TBL] [Abstract][Full Text] [Related]
20. Translating Antisense Technology into a Treatment for Huntington's Disease. Lane RM; Smith A; Baumann T; Gleichmann M; Norris D; Bennett CF; Kordasiewicz H Methods Mol Biol; 2018; 1780():497-523. PubMed ID: 29856033 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]